论文部分内容阅读
本文报告用尿激酶(以下简称UK.)治疗20例脑血管闭塞性疾病的效果。并且与用“常规药物”进行治疗的20例进行了比较。结果表明UK.组开始见效时间,主要集中于疗程的前4天,而且前4天中的任何一天,共有效病例数均与对照组有显著性差异。但10天内总的有效率两组无显著性差异(UK.组为60％;对照组50％)。 在分析其原因时,结合复习有关文献,我们讨论了两个问题:1.小剂量UK.治疗本病的作用机制:可能为激活机体内在的纾溶系统、阻止血栓的进展、改善侧枝血循。2.应用UK.治疗本病的某些值得注意之点:选择适应症,力争早期用药,开始剂量为40,000～80,000单位/日,分次给药,静脉缓慢注射较静脉点滴为好,配合“常规药物”比单用UK为洼。疗程4～7天,逐渐减量。
This article reports the efficacy of urokinase (hereinafter referred to as UK.) In the treatment of 20 patients with cerebrovascular occlusive disease. And compared with 20 cases treated with “conventional drugs”. The results showed that the UK group began to work with time, mainly in the first 4 days of treatment, and the first 4 days in any one day, the total number of valid cases were significantly different from the control group. However, there was no significant difference between the two groups in overall efficacy over 10 days (UK, 60%; control, 50%). In analyzing its causes, combined with the review of the literature, we discussed two issues: 1. Low-dose UK. The mechanism of action for the treatment of this disease: may be to activate the body’s internal remission system to stop the progress of thrombus and improve collateral blood Follow. 2. Application UK. Some of the treatment of this disease worth noting: Indications, and strive for early medication, the start dose of 40,000 ~ 80,000 units / day, sub-administration, intravenous injection of venous injection is better than the slow, with the “ Conventional drugs ”than the UK alone for depression. Course of 4 to 7 days, tapering.